{"id":"continuous-infusion-of-cefoxitin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Hypersensitivity reactions"},{"rate":"1-2","effect":"Diarrhea"},{"rate":"1-2","effect":"Phlebitis at infusion site"},{"rate":"0.5-1","effect":"Nausea"},{"rate":"0.5-2","effect":"Clostridium difficile-associated diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefoxitin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. As a second-generation cephalosporin, it has broader gram-negative coverage than first-generation agents and is particularly effective against anaerobic bacteria. Continuous infusion delivery maintains sustained bactericidal concentrations at the infection site.","oneSentence":"Cefoxitin is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:38.489Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Surgical site infection prophylaxis"},{"name":"Intra-abdominal infections"},{"name":"Gynecological infections"},{"name":"Mixed aerobic-anaerobic infections"}]},"trialDetails":[{"nctId":"NCT05755789","phase":"PHASE3","title":"Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2023-06-22","conditions":"Antibiotic Prophylaxis, Colorectal Surgery","enrollment":2000},{"nctId":"NCT02560207","phase":"PHASE4","title":"Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2015-11","conditions":"Critically Ill","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Continuous infusion of cefoxitin","genericName":"Continuous infusion of cefoxitin","companyName":"Poitiers University Hospital","companyId":"poitiers-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefoxitin is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Surgical site infection prophylaxis, Intra-abdominal infections, Gynecological infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}